A Review of Emerging Neoadjuvant Intravesical Strategies to Enhance Systemic Immune Checkpoint Blockade in Patients with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Through the Induction of Immunogenic Cell Death and Activation of Tertiary Lymphoid Structure Formation